All In Biotech

Drug Trial Radar · NCT03382574

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

Last checked: Nov 19, 2026Latest source record: Jun 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

2

Actual

Start

Mar 14, 2019

Primary completion

Oct 22, 2021

Study completion Oct 22, 2021

Sponsor

Sponsor type
NIH
First posted
Dec 26, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized pilot early phase I trial studies how well denosumab works in BRCA1/2 mutations carriers scheduled for risk-reducing salpingo-oophorectomy. Denosumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.

Conditions

  • Ovarian Carcinoma

Interventions

  • DenosumabBiological

    Given SC

  • Salpingo-OophorectomyProcedure

    Undergo risk-reducing salpingo-oophorectomy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ki67 Proliferation Index Fallopian Tube Fimbrial Epithelial CellsTime frame: Up to 12 months

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

    New York, New York

  • NYP/Weill Cornell Medical Center

    New York, New York

  • M D Anderson Cancer Center

    Houston, Texas

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

  • Chaim Sheba Medical Center

    Tel HaShomer, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.